CenExel is proud to highlight the poster presented at the Annual Meeting of the International Society for CNS Clinical Trials and Methodology Conference, February 2018, Washington,...
CenExel is proud to highlight the poster presented at the Annual CNS Summit Meeting, November 2018, Boca Raton, FL. ABSTRACT Introduction: This investigation is the first known...
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal,...
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal,...
MIAMI, Jul. 27, 2020 – Dr. Howard Schwartz, Chief Medical Officer and Principal Investigator for vaccine trials at Research Centers of America (RCA), a CenExel...
TLC590 showed faster and longer lasting pain relief than ropivacaine SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan – October 21, 2019 – TLC (Nasdaq: TLC,...
Webster Capital-based CenExcel Clinical Research Inc. (CenExel) was formed in 2018 with the merger of JBR Clinical Research, a Salt Lake City facility specializing in...
Companies seeking to evaluate new analgesic entities face two critical early choices: which pain model to utilize and which research site(s) with which to partner....
Salt Lake City, Utah – July 18, 2019 – CenExel Clinical Research, Inc., (“CenExel” or the “Company”) announces the creation of their Centers of Excellence...
